Towards the development of neo-antigen-targeted, personalized immunotherapies for advanced colorectal cancer patients.
- Conditions
- Colorectal cancerColorectal carcinoma10017990
- Registration Number
- NL-OMON42438
- Lead Sponsor
- eids Universitair Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
Tumors analysed will be derived from CRC patients diagnosed with high-risk stage II (IIC), stage III and IV colorectal cancers.
At least 20% of the patients participating in the study should be individuals diagnosed with colorectal cancer until de age of 50 years-old.
Exclusion Criteria
Severe anemia (Hb < 6.0 mmol/L)
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The main study endpoint consists in determining the percentage of advanced CRC<br /><br>patients that carry T-cells with the ability to recognize cancer neo-antigens<br /><br>in an autologous setting. Thereby the percentage of CRC patients that can<br /><br>benefit from neo-antigen-targeted therapies will also be estimated.</p><br>
- Secondary Outcome Measures
Name Time Method <p>NA</p><br>